ArticleBriefings in bioinformatics2026
NyxBind: enhancing deep neural representations for transcription factor binding site prediction via contrastive learning.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Although pretrained genomic language models effectively capture general DNA sequence patterns through masked language modeling, they often struggle to discriminate subtle yet biologically critical differences among transcription factor binding site (TFBS) motifs. Recent studies suggest that contrastive learning can enhance the discriminative power of embeddings by explicitly modeling inter-instance similarities and differences. Building on this insight, we introduce NyxBind, a TFBS prediction model that applies contrastive learning across multiple TFBS types to enhance regulatory sequence representations. Across 159 TFBS prediction tasks, NyxBind achieves the best performance on all evaluation metrics and improves Matthews Correlation Coefficient by 4.71 percentage points over DNABERT2. NyxBind supports both full-parameter and parameter-efficient fine-tuning while maintaining strong performance. It also enables accurate motif visualization, with results closely matching experimentally validated transcription factor binding profiles.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.